2018-05-07
Sustainability and affordability of cancer drugs: a novel pricing model
Publication
Publication
Nature Reviews Clinical Oncology p. 1- 2
The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.
| Additional Metadata | |
|---|---|
| doi.org/10.1038/s41571-018-0027-x, hdl.handle.net/1765/106296 | |
| Nature Reviews Clinical Oncology | |
| Organisation | Institute for Medical Technology Assessment (iMTA) |
|
Uyl-de Groot, C., & Löwenberg, B. (2018). Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 1–2. doi:10.1038/s41571-018-0027-x |
|